Search tips
Search criteria 


Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
J Clin Invest. 2008 April 1; 118(4): 1417–1426.
Published online 2008 March 13. doi:  10.1172/JCI30065
PMCID: PMC2267033

IRF9 and STAT1 are required for IgG autoantibody production and B cell expression of TLR7 in mice


A hallmark of SLE is the production of high-titer, high-affinity, isotype-switched IgG autoantibodies directed against nucleic acid–associated antigens. Several studies have established a role for both type I IFN (IFN-I) and the activation of TLRs by nucleic acid–associated autoantigens in the pathogenesis of this disease. Here, we demonstrate that 2 IFN-I signaling molecules, IFN regulatory factor 9 (IRF9) and STAT1, were required for the production of IgG autoantibodies in the pristane-induced mouse model of SLE. In addition, levels of IgM autoantibodies were increased in pristane-treated Irf9–/– mice, suggesting that IRF9 plays a role in isotype switching in response to self antigens. Upregulation of TLR7 by IFN-α was greatly reduced in Irf9–/– and Stat1–/– B cells. Irf9–/– B cells were incapable of being activated through TLR7, and Stat1–/– B cells were impaired in activation through both TLR7 and TLR9. These data may reveal a novel role for IFN-I signaling molecules in both TLR-specific B cell responses and production of IgG autoantibodies directed against nucleic acid–associated autoantigens. Our results suggest that IFN-I is upstream of TLR signaling in the activation of autoreactive B cells in SLE.


SLE is a chronic autoimmune disease characterized by the inflammatory destruction of many organ systems including skin, blood elements, joints, kidneys, and other tissues. A hallmark of lupus is the production of high-titer IgG autoantibodies that recognize primarily nuclear autoantigens, many of which contain nucleic acids. Several studies have indicated a pathogenic role for the type I IFN (IFN-I) system in human SLE patients. An increase in serum IFN-α in SLE patients was first noted in 1979 (1). Expression profiling of SLE patient blood reveals an IFN-I–inducible gene expression signature in peripheral blood cells (24) as well as increased serum levels of IFN-inducible cytokines and chemokines (5). A causative role for IFN-I in the pathogenesis of SLE is demonstrated by the observation that a subset of patients treated with recombinant IFN-α for nonautoimmune disorders develop a lupus-like syndrome that resolves when IFN-α therapy is discontinued (6).

All members of the IFN-I family, including 13 subtypes of IFN-α and IFN-β, bind to the same receptor, IFN (α and β) receptor (IFNAR). Both IFN-I and IFN-γ signal through STAT1, and Stat1–/– mice fail to upregulate IFN-inducible genes in response to IFN-I or IFN-γ (7). IFN-I signal transduction results in activation of the IFN-stimulated gene factor 3 (ISGF3) heterotrimeric complex, which is composed of STAT1, STAT2, and IFN regulatory factor 9 (IRF9). Upon engagement of IFNAR by IFN-Is, ISGF3 translocates to the nucleus and induces transcription of IFN-I–regulated genes. Irf9–/– mice fail to upregulate IFN-inducible genes in response to IFN-I (8). The induction of IFN-α and IFN-β is severely impaired in these mice (9). Evidence exists that IRF9 can bind to STAT1 homodimers in response to IFN-γ stimulation (10) and that the ISGF3 complex can form in response to IFN-γ (11). The induction of guanylate binding protein was impaired in response to IFN-α, but not IFN-γ, in Irf9–/– embryonic fibroblasts (8), suggesting that IRF9 is required for IFN-I, but not IFN-γ, signaling in vivo. Crosstalk between these 2 pathways has been well established, and both pathways play an important role in the development of autoimmunity.

The production of IgG autoantibodies directed against ribonucleoproteins (RNPs), including components of the U1 small nuclear RNP/Smith antigen (U1snRNP/Sm) complex, the Ro/La complex, and ribosomal phosphoprotein P0 (RiboP), is a hallmark of SLE and mixed connective tissue disease (MCTD). The overexpression of IFN-I–inducible genes correlates with the production of anti-RNP autoantibodies in SLE patients (4, 12, 13). In the pristane model of SLE, BALB/c mice given a single i.p. injection of the mineral oil pristane develop a lupus-like disease characterized by the production of anti-U1snRNP/Sm, anti-RiboP, and anti-DNA autoantibodies and the development of inflammatory kidney disease (1416). Pristane treatment induces apoptosis (17), formation of peritoneal lipogranulomas that express high levels of IFN-I–inducible genes (18), and hypergammaglobulinemia characterized by high levels of the pathogenic isotype IgG2a (19). This model therefore recapitulates key features of SLE pathogenesis in humans including hypergammaglobulinemia, anti-RNP autoantibody production, kidney disease, defects in clearance of apoptotic debris, and upregulation of IFN-I–inducible genes.

Although aberrations in the IFN-I system have been associated with SLE since as early as 1979 (1), the mechanisms by which this pathway becomes activated have remained elusive until the recent characterization of the nucleic acid–sensing TLRs: TLR7, which recognizes ssRNA; and TLR9, which recognizes dsDNA. A serum factor in SLE patients capable of inducing IFN-I production in normal blood leukocytes was first noted in 1999 (20) and was subsequently identified as circulating immune complexes containing nucleic acid–associated autoantigens (21, 22). It was later shown that DNA-containing immune complexes could induce IFN-I production in plasmacytoid dendritic cells (pDCs) through the cooperation of FcγRIIa and TLR9 (23). DNA-containing immune complexes can activate autoreactive B cells by dual engagement of the B cell receptor and TLR9 (24). Likewise, the RNA components of autoantigens, such as the U1-RNA and the Y-RNAs associated with the Ro/La complex, activate B cells and pDCs through the engagement of TLR7 (2531). In murine SLE models, TLR9 is necessary for anti-dsDNA autoantibody production and antibody class switching to the pathogenic IgG2a and IgG2b isotypes (32, 33). TLR7 is both necessary (33) and sufficient (34, 35) for the induction of autoantibodies that recognize RNPs in lupus mouse models. It is hypothesized that ligation of TLRs by the nucleic acid components of SLE-associated autoantigens and the subsequent induction of IFN-I may drive the immune response against nucleic acid–containing autoantigens in SLE.

We have previously used autoantigen microarrays to profile the autoantibody response in human and murine autoimmune diseases (16, 3641). In the current study, we used this technology to profile the autoantibody response in pristane-treated mice deficient for the IFN-I signaling molecules IRF9 and STAT1. Our results demonstrated that the development of IgG autoantibodies directed against prominent, clinically assayed SLE and MCTD autoantigens was dependent on IRF9 and STAT1. Pristane-treated Irf9–/– mice developed significantly higher titers of IgM autoantibodies, indicating a potential role for this molecule in isotype switching. B cells from Irf9–/– and Stat1–/– mice exhibited specific defects in expression of TLR7 and response to TLR7 ligands. We demonstrated what we believe to be a novel role for IFN-I signaling molecules in TLR-specific B cell responses and the development of autoantibodies in vivo.



To examine the role of signaling molecules downstream of the IFNAR in development of SLE, we treated WT, Irf9–/–, and Stat1–/– mice, all on the BALB/c background, with pristane or PBS as a negative control. IFN-I stimulates isotype switching to all subclasses of IgG (42) and, in combination with IL-6, induces B cell maturation into plasma cells that secrete high levels of IgG (43). In addition, IFN-γ, which also signals through STAT1, is critical for isotype switching to the pathogenic IgG2a isotype (44). Pristane treatment induced hypergammaglobulinemia in WT mice; however, levels of total serum IgG as well as IgG2a were significantly decreased in pristane-treated Irf9–/– and Stat1–/– mice (Figure (Figure1).1). Interestingly, pristane-treated Irf9–/– mice developed significantly higher levels of total serum IgM, consistent with a role for IFN-I signaling in isotype switching. In contrast, levels of serum IgM in pristane-treated Stat1–/– mice were significantly decreased compared with those in pristane-treated WT mice. There were no differences in the serum levels of IgG1, IgG2b, or IgG3 between pristane-treated WT and Irf9–/– mice; however, Stat1–/– mice had significantly decreased levels of IgG2b and IgG3.

Figure 1
Serum Ig isotype levels in pristane-treated mice.

Autoantibody production.

We used autoantigen microarrays to profile the autoantibody response in WT, Irf9–/–, and Stat1–/– mice treated with pristane or PBS. The lupus arrays contained 616 features consisting of more than 50 proteins, peptides, and nucleic acids that are candidate autoantigens in human and murine SLE. We used a hierarchical clustering program (45) to order individual mice on the basis of similarity of autoantibody profiles. Cluster results were displayed as a heatmap (Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI30065DS1) using Java Treeview software (46). We used the significance analysis of microarrays (SAM) algorithm (47) to determine statistically significant differences in array reactivity between groups of animals. Pairwise SAM comparison of PBS-treated mice with pristane-treated WT mice revealed significantly increased reactivity to 15 antigens in pristane-treated WT mice (Supplemental Figure 2). SAM identified many autoantigens known to be targeted in this model, including single-stranded DNA (ssDNA), histones, components of the Sm/RNP complex (BB′, Sm/RNP, U1A, U1C, and U1-70kD), and RiboP. Next, we compared the autoantibody profiles of pristane-treated WT mice with those of pristane-treated Irf9–/– mice. SAM identified reactivity to 4 antigens as significantly increased in serum from pristane-treated WT mice compared with pristane-treated Irf9–/– mice (false discovery rate [FDR], <0.05). These antigens included 3 components of the Sm/RNP complex (U1A, BB′, and Sm) and RiboP. Interestingly, all 4 polypeptides are components of RNA-associated autoantigen complexes.

In addition to analyzing the data using hierarchical clustering and a rigorous statistical algorithm, we validated all array findings using conventional techniques including immunoprecipitation and ELISA (see Supplemental Figure 3 for correlation plots of ELISA versus array values). WT mice treated with pristane develop autoantibodies capable of immunoprecipitating components of the Sm/RNP complex (15). Because SAM identified reactivity to 3 components of this complex as significantly increased in pristane-treated WT versus pristane-treated Irf9–/– mice, we examined the ability of serum autoantibodies to immunoprecipitate the Sm/RNP complex. Sera from 8 of 15 (53%) pristane-treated WT mice immunoprecipitated this complex (Table (Table1);1); in striking contrast, all serum samples from Irf9–/– (n = 15) and Stat1–/– (n = 11) mice treated with pristane failed to immunoprecipitate the Sm/RNP complex.

Table 1
Immunoprecipitation of the Sm/RNP complex

We also used conventional ELISA to determine the titers of autoantibodies directed against the 2 RNA-associated complexes identified as significant on the arrays. IRF9 was required for the development of IgG autoantibodies directed against Sm/RNP and RiboP (Figure (Figure2,2, B and C). Interestingly, in contrast to the phenotype for IgG, the titer of IgM autoantibodies directed against these 2 complexes was significantly increased in pristane-treated Irf9–/– mice (Figure (Figure2,2, B and C). The secondary reagent used for the array studies recognizes both IgG and IgM antibodies. Therefore, the high titers of IgM autoantibodies in pristane-treated Irf9–/– mice may explain the weak reactivity to the 4 SAM-identified autoantigens in this group of mice (Figure (Figure2A).2A). These findings identify an IRF9-dependent defect in isotype switching from IgM to pathogenic IgG autoantibodies directed against RNA-associated autoantigens.

Figure 2
Pristane-treated Irf9–/– mice lack isotype-switched IgG autoantibodies specific for nucleic acid–associated autoantigens but produce high titers of IgM anti-RNP autoantibodies.

Pristane-treated WT mice also develop high titers of IgG anti-ssDNA and anti-histone autoantibodies (48). We examined the production of autoantibodies directed against these DNA-associated autoantigens using conventional ELISA. IgG anti-ssDNA and anti-histone autoantibody levels were significantly decreased in pristane-treated Irf9–/– mice compared with pristane-treated WT mice (Figure (Figure2,2, D and E). Although the titer of IgM autoantibodies directed against DNA-associated autoantigens was increased in pristane-treated compared with PBS-treated Irf9–/– mice, there was no significant increase in IgM titers of anti-ssDNA or anti-histone autoantibodies between pristane-treated WT and Irf9–/– mice (Figure (Figure2,2, D and E). We also tested for the presence of anti-dsDNA autoantibodies in the serum of pristane-treated WT and Irf9–/– mice using Crithidia luciliae immunofluorescence assays. At 9 months following pristane treatment, serum from 2 of 15 (13%) WT mice demonstrated positive staining of the C. luciliae kinetoplast, whereas no serum samples from Irf9–/– mice were positive (D.L. Thibault and P.J. Utz, unpublished observations). Therefore, we conclude that IRF9 is required for the production of isotype-switched IgG autoantibodies against both RNA- and DNA-associated targets. Titers of IgG isotypes directed against Sm/RNP and ssDNA are shown in Supplemental Figure 4.

We next examined the production of autoantibodies in pristane-treated Stat1–/– mice. The SAM algorithm revealed reactivity to several components of the Sm/RNP complex (U1A, Sm/RNP, BB′, U1C, and Sm) as well as RiboP, azurocidin, and BPI as significantly increased in pristane-treated WT mice versus pristane-treated Stat1–/– mice (FDR, <0.05; Figure Figure3A).3A). Conventional ELISA studies revealed that, unlike the phenotype for pristane-treated Irf9–/– mice, pristane-treated Stat1–/– mice had significantly lower levels of both IgG and IgM autoantibodies against Sm/RNP, RiboP, and ssDNA versus pristane-treated WT mice (Figure (Figure3,3, B–D). Levels of IgG autoantibodies against total histone proteins were also significantly decreased in pristane-treated Stat1–/– mice; however, there was no difference in the levels of IgM anti-histone autoantibodies (Figure (Figure3E).3E). Taken together, these data demonstrate a critical role for IFN-I signaling molecules in the development of high-titer, isotype-switched, IgG autoantibodies directed against prominent nucleic acid–containing SLE autoantigens. They further reveal an important role for IRF9, but not STAT1, in isotype switching to IgG in response to RNA-associated autoantigens.

Figure 3
Pristane-treated Stat1–/– mice lack IgG and IgM autoantibodies specific for nucleic acid–associated autoantigens.

TLR7 and TLR9 expression.

The nucleic acid components of SLE autoantigens have previously been shown to activate autoreactive B cells through the nucleic acid–sensing TLR7, which recognizes RNA, and TLR9, which recognizes DNA. One study demonstrated that IFN-I secreted by pDCs induces the expression of TLR7 but not TLR9 in human naive B cells (49). The proliferation of autoreactive B cells in response to RNA-associated immune complexes is enhanced by IFN-I, presumably due to its ability to enhance TLR7 expression (29). We hypothesized that there may be defects in the expression of TLR7 and TLR9 in B cells from Irf9–/– mice. Splenic B cells were purified from WT and Irf9–/– mice, RNA was extracted, and the relative expression of TLR7 and TLR9 normalized to GAPDH was determined by real-time quantitative PCR. B cells from Irf9–/– mice expressed significantly lower levels of TLR7 mRNA than did WT B cells; however, there was no significant difference in the expression of TLR9 (Figure (Figure4A).4A). We next examined the ability of IFN-I to enhance the expression of TLRs in B cells. Purified B cells from WT or Irf9–/– mice were cultured in the presence or absence of recombinant IFN-α. As expected, the induction of expression of a known IFN-I–inducible gene, Mx1, was completely abolished in B cells from Irf9–/– mice following IFN-α treatment (Figure (Figure4B).4B). The expression of TLR7 was upregulated more than 20-fold in IFN-α–treated B cells from WT mice, but this upregulation was almost completely inhibited in B cells from Irf9–/– mice (Figure (Figure4B).4B). In contrast to results previously obtained in human B cells (49), IFN-α enhanced the expression of TLR9 in WT B cells approximately 3-fold. This upregulation was abolished in Irf9–/– B cells. Therefore, IRF9 mediates the IFN-I–inducible expression of TLR7 and TLR9 in murine B cells. We also examined the expression of TLR7 and TLR9 in B cells from Stat1–/– mice. Similar to the phenotype for Irf9–/– B cells, Stat1–/– B cells failed to upregulate the expression of TLR7 and TLR9 following IFN-α stimulation (Supplemental Figure 5). We conclude that IRF9 and STAT1 are critical for the expression of nucleic acid–sensing TLRs in B cells and are required for the induction of TLR expression by IFN-I.

Figure 4
IRF9 is required for expression of, and activation through, TLR7 in B cells.

TLR7 and TLR9 activation.

To determine whether differences in TLR7 and TLR9 expression had functional consequences on Irf9–/– B cell activation, we examined the ability of Irf9–/– B cells to respond to TLR7 and TLR9 agonists. We stimulated whole splenocytes and purified B cells from WT and Irf9–/– mice with a TLR7-activating ssRNA analog, loxoribine, or a TLR9-activating CpG-containing oligodeoxynucleotide (ODN), ODN1826. Both proliferation (Figure (Figure4,4, C and D) and IL-6 secretion (Figure (Figure4,4, E and F) were significantly decreased in Irf9–/– splenocytes and purified B cells in response to the TLR7 agonist. Whole splenocytes from Irf9–/– mice proliferated slightly more in response to the TLR9 ligand (Figure (Figure4C),4C), whereas no difference in B cell proliferation (Figure (Figure4D)4D) or secretion of IL-6 by whole splenocytes (Figure (Figure4E)4E) or purified B cells (Figure (Figure4F)4F) was observed in response to this ligand. These data indicate functional defects in TLR7-specific B cell responses in Irf9–/– mice. Because IFN-α induced very high levels of TLR7 expression in B cells from WT mice but not Irf9–/– mice, we examined the secretion of IL-6 in response to TLR ligands following treatment with IFN-α. Although pretreatment with IFN-α increased the level of IL-6 secretion by purified B cells in response to loxoribine in both WT and Irf9–/– mice, these levels were significantly lower in B cells from Irf9–/– mice than in those from WT mice (Figure (Figure4G).4G). IFN-α pretreatment enhanced B cell secretion of IL-6 in response to ODN1826; however, there was no difference between WT and Irf9–/– mice.

Stat1–/– B cells also displayed defects in responses to TLR7 agonists (Supplemental Figure 5). In particular, Stat1–/– splenocytes and purified B cells proliferated less and secreted less IL-6 upon stimulation with loxoribine compared with cells from WT mice. Unlike Irf9–/– mice, splenocytes and purified B cells from Stat1–/– mice proliferated significantly less and secreted less IL-6 in response to a CpG-containing TLR9 agonist (Supplemental Figure 5, C–F). Stat1–/– B cells pretreated with IFN-α failed to upregulate secretion of IL-6 upon stimulation with both TLR7 and TLR9 agonists (Supplemental Figure 5G). We have therefore identified deficiencies in TLR expression and in TLR7-specific responses in B cells that lack critical IFN-I signaling molecules. Our data suggest that IRF9 and STAT1 are central mediators of TLR7- and TLR9-specific B cell responses and that activation of these pathways may lead to antigen-specific IgG autoantibody responses in vivo.

Adjuvant-enhanced antibody responses.

Recently it has been suggested that adjuvant-enhanced antibody responses do not require TLR signaling in vivo (50). Because Irf9–/– mice exhibited specific defects in isotype switching to IgG in the pristane model, we asked whether there were global defects in isotype switching or whether this defect in IgG antibody response was limited to nucleic acid–containing self antigens with the capacity to ligate TLR7 and/or TLR9. We immunized WT and Irf9–/– mice with OVA in CFA on day 0, boosted with OVA in incomplete Freund adjuvant (IFA) on day 14, and measured anti-OVA antibody titers on day 28. There were no significant differences in levels of IgM, IgG, IgG1, IgG2a, IgG2b, or IgG3 anti-OVA antibodies between WT and Irf9–/– mice (Figure (Figure5).5). We conclude that unlike the phenotype for TLR-dependent autoantigens, B cells from Irf9–/– mice are capable of isotype switching to all subtypes of IgG in response to a foreign antigen together with a strong stimulus such as CFA. These data also demonstrate that there are no global defects in B cell activation, B cell signaling, B cell maturation, affinity maturation, or isotype switching in Irf9–/– mice in vivo.

Figure 5
Irf9–/– mice mount an effective IgG antibody response when immunized with OVA in CFA.

Kidney disease and plasmacytoma development.

The development of proteinuria, a measure of kidney disease, was assessed in WT, Irf9–/–, and Stat1–/– mice treated with PBS and pristane (Table (Table2).2). As expected, about half of WT mice primed with pristane developed proteinuria over the course of 12 months. None of the pristane-treated Irf9–/– mice developed proteinuria, suggesting that IRF9 may play a role in the development of nephritis. One Stat1–/– mouse treated with pristane developed proteinuria, and this mouse also developed very severe ascites as the result of plasmacytoma induction. Following the completion of the study at 12 months, kidneys were harvested from the remaining mice, sectioned, and stained with hematoxylin and eosin, after which the extent of kidney damage was scored according to standard NIH activity and chronicity indices (51) in a blinded manner by a single investigator (see Supplemental Table 1 for detailed description of extent and type of kidney pathology). The overall extent of kidney damage was not severe in the pristane-treated WT group, which had an average activity score of 0.23 out of a possible 4 (Supplemental Table 1). None of 6 pristane-treated Irf9–/– or 5 pristane-treated Stat1–/– mice examined developed any changes in activity index. Taken together, these data suggest a role for IFN-I signaling molecules in the end-organ pathogenesis of lupus nephritis.

Table 2
Development of proteinuria

One major caveat of these findings was that a high percentage of pristane-treated Irf9–/– mice developed fatal ascites prior to the conclusion of the study as a result of plasmacytoma induction. Approximately 20% of BALB/c mice primed with a single injection of pristane develop plasmacytomas driven by chronic inflammation in the peritoneal cavity (52). The development of ascites in pristane-treated WT, Irf9–/–, and Stat1–/– mice was plotted as a Kaplan-Meier curve (Supplemental Figure 6). Induction of plasmacytoma was confirmed by cytological analysis of ascites fluid (D.L. Thibault and P.J. Utz, unpublished observations). The median survival time of pristane-treated Irf9–/– mice was 11 months, and 67% of the mice developed fatal ascites before the conclusion of the study. Stat1–/– mice displayed a greatly accelerated course of ascites development (median survival time, 8 months), and 65% of mice developed ascites over the course of 12 months. The anti-neoplastic properties of IFNs have been well documented, and STAT1 mediates the antiproliferative and proapoptotic effects of both IFN-Is and IFN-γ (53, 54). Recombinant IFN-α has been used successfully to treat a variety of malignancies (55). The higher rate of plasmacytoma induction in both Irf9–/– and Stat1–/– mice is therefore not surprising given their susceptible BALB/c genetic background, although the mechanism of this induction remains to be elucidated. It is possible that some Irf9–/– mice may have gone on to developed proteinuria or kidney damage had they survived. WT mice primed with pristane, however, did not develop the extensive kidney pathology seen in other spontaneous models of SLE such as MRL/lpr and (NZB × NZW)F1. We are in the process of backcrossing Irf9–/– and Stat1–/– mice to these models to more carefully assess the contribution of these molecule to end-organ kidney damage.


Since the original clinical and serological description of MCTD by Sharp and colleagues in this journal (56), many hypotheses have been put forward regarding the mechanisms by which high-titer IgG autoantibodies against the U1snRNP and other nucleic acid–containing autoantigens become immunogenic. Cross-reactivity with viral antigens such as U1-70K and the retroviral protein p30gag (57), coassociation of RNPs with viral antigens such as EBER1 and EBER2 (58), and apoptosis-specific modifications of many components of the U1snRNP (59) have all been suggested to play important roles in the immunogenicity of the U1snRNP. Our present results do not refute these models, but identify a central, in vivo role for 2 molecules downstream of IFNAR in the production of IgG autoantibodies capable of immunoprecipitating RNP complexes targeted in MCTD and SLE, including the U1snRNP and RiboP.

In the current study, we describe the autoantibody response in mice deficient for IRF9 and STAT1, critical downstream mediators of IFN-I signaling. Our initial screen using autoantigen microarrays followed by rigorous statistical analysis using SAM revealed 4 significantly different antigens between pristane-treated WT and Irf9–/– mice, all of which are associated with RNPs. Further validation using conventional techniques demonstrated that IRF9 and STAT1 were required for the development of IgG autoantibodies to several different nucleic acid–associated complexes targeted in this model. In contrast, Irf9–/– mice mounted an effective IgG antibody response against a foreign antigen when immunized with the strong adjuvant CFA. Irf9–/– and Stat1–/– B cells had specific defects in expression of, and activation through, the nucleic acid–sensing TLRs, suggesting that defects in TLR7- and TLR9-dependent B cell responses may account for the lack of isotype-switched IgG autoantibodies.

The ISGF3 complex, composed of STAT1, STAT2, and IRF9, has also been shown to form upon activation by IFN-γ (10, 11). ISGF3 formation in response to IFN-γ treatment occurred at higher levels following pretreatment with IFN-α, which upregulates the expression of STAT1 and IRF9, or in the presence of highly overexpressed STAT1 and IRF9 (10). The in vivo relevance of this pathway has not yet been established, and it is possible that IRF9 mediates signals through both the IFNAR and the IFN-γ receptor. To more directly address the role of the IFN-I pathway in the development of autoimmunity, we have initiated similar studies in pristane-treated mice deficient for the IFNAR2 chain of the IFNAR. Preliminary data suggest that pristane-treated Ifnar2–/– mice have a phenotype similar to that seen in pristane-treated Irf9–/– mice (D.L. Thibault and P.J. Utz, unpublished observations). Specifically, the production of IgG autoantibodies, and the expression of nucleic acid–sensing TLRs in B cells, was completely dependent on IFNAR2. Levels of total serum IgM were significantly increased in pristane-treated Ifnar2–/– mice, and these mice developed high titers of IgM autoantibodies, suggesting a defect in isotype switching similar to that seen in Irf9–/– mice. In addition, pristane-treated Ifnar1–/– mice failed to develop anti-RNP autoantibodies; however, the expression of TLRs and the isotypes of the autoantibodies were not assessed in this study (60). This differs from the autoantibody phenotype seen in pristane-treated IFN-γ–deficient mice, in which IFN-γ was not absolutely required for the development of high titers of IgG autoantibodies capable of precipitating the Sm/RNP complex (ref. 61 and D.L. Thibault, K.L. Graham, and P.J. Utz, unpublished observations). These data suggest that IRF9 mediates signals downstream of the IFNAR, but not downstream of the IFN-γ receptor, and that IFN-I drives the autoimmune response to RNA-associated autoantigens in vivo.

Molecules involved in the negative regulation of both TLR and IFN signaling pathways have previously been identified. In particular, the TAM receptors, which include Tyro3, Axl, and Mer, are pleiotropic inhibitors of TLR- and cytokine-induced signaling, and control the induction of SOCS-1 by IFN-α (62). Both Socs1–/– and TAM receptor triple-knockout mice develop spontaneous autoimmunity (63, 64), highlighting the critical role of negative regulation of the TLR and IFN pathways in the development of autoimmunity. The TAM receptors have previously been shown to be directly associated with IFNAR1, and Stat1–/– mice display defects in TAM receptor function (62). TAM-mediated induction of the molecule Twist results in the suppression of TNF-α production (65), demonstrating a mechanism by which IFN-I mediates the suppression of TNF-α. The role of these molecules in the development of autoimmunity in the pristane model, as well as their function in Irf9–/– mice, will need to be assessed in future studies.

The 9 known members of the IRF family play roles in the induction of IFN-regulated genes and of IFN-Is themselves (66). Recent publications have highlighted important potential roles for members of the IRF family in the pathogenesis of SLE. A common haplotype of IRF5 is a genetic risk factor for human SLE (6769). Both IRF7 and IRF5 are critical for DC production of IFN-α, IFN-β, and IL-6 by anti-RNP immune complexes and by conventional TLR7 and TLR9 ligands (70, 71). MRL/lpr mice lacking the IRF1 gene develop less severe disease compared with WT mice (72). Finally, female mice deficient for IRF4-binding protein develop a lupus-like disease characterized by hypergammaglobulinemia, autoantibody production, and immune complex–mediated glomerulonephritis (73). To our knowledge, a role for IRF9 has not previously been addressed in the contexts of SLE or TLR signaling. Our present results suggest this molecule is a critical mediator of B cell responses, including autoantibody production, isotype switching, and the expression of and activation through nucleic acid–sensing TLRs.

The pristane model offers a unique opportunity to study the role of the IFN-I pathway in the development of murine SLE. Several recent studies have examined the contributions of TLRs and IFN-I to SLE disease in the MRL/lpr model (33, 74, 75). DNA microarray analysis of MRL/lpr splenocyte subsets and kidneys clearly demonstrate an IFN-γ–regulated gene expression profile, whereas genes induced by IFN-I are not upregulated in MRL/lpr mice (76). This observation may explain why MRL/lpr mice deficient for the IFNAR1 chain of the IFNAR actually develop more severe disease: the lack of IFN-I signaling may further drive the IFN-γ response (75). In contrast to the MRL/lpr model, several IFN-I–inducible genes are upregulated in pristane-induced ectopic lymphoid tissue and peripheral blood mononuclear cells (18, 60), which mirrors the gene expression profile seen in human lupus patients (24, 12, 13). In human SLE patients, high expression of these genes correlates with the production of anti-nucleoprotein and, in particular, anti-RNP autoantibodies (12, 13). (NZB × NZW)F1 mice do not develop autoantibodies that recognize RNA-containing autoantigens, although administration of pristane to these mice resulted in an accelerated disease course and induced the production of anti-RNP autoantibodies (77). Therefore, disease pathogenesis in the pristane model, especially in regard to dysregulation of the IFN-I pathway, more closely resembles human SLE when compared with the spontaneous models described above. To more carefully assess the contribution of this pathway to lupus nephritis, further studies in these spontaneous models will be necessary.

Several recent studies have described the ability of nucleic acid–containing MCTD and SLE autoantigens to stimulate autoreactive B cells through nucleic acid–sensing TLRs. Here we demonstrated that IFN-I signaling components controlled the ability of B cells to upregulate the expression of TLR7 and TLR9 upon stimulation with IFN-α. The expression of TLR7 in particular was influenced by IFN-I, because its expression was enhanced more than 20-fold upon incubation with IFN-α in WT B cells. Interestingly, although B cell expression of TLR7 and secretion of IL-6 in response to a TLR7 agonist was dramatically reduced in Irf9–/– mice following treatment with IFN-α (Figure (Figure4,4, B and G), TLR7 expression and activation were slightly enhanced by IFN-α in the absence of IRF9. Residual TLR7 expression following IFN-α treatment was sufficient for the secretion of lower levels of IL-6, suggesting that expression of TLR7 is partially IRF9 independent in B cells. We propose that residual expression of TLR7 may drive the partial activation of autoreactive B cells and the subsequent production of IgM-specific autoantibodies.

IRF9 is absolutely required for isotype switching to pathogenic, high-titer, high-affinity IgG autoantibodies. This is not caused by global defects in isotype switching in Irf9–/– B cells, because there was no defect in adjuvant-enhanced isotype switching to all subtypes of IgG against a foreign antigen (Figure (Figure5).5). Unlike pristane-treated Irf9–/– mice, pristane-treated Stat1–/– mice did not develop high titers of total serum IgM or IgM-specific autoantibodies. Both PBS- and pristane-treated Stat1–/– mice had very low serum titers of all antibody isotypes except for IgG1, and B cells from Stat1–/– mice displayed a decreased ability to respond to multiple stimuli, including TLR7 and TLR9, and decreased crosslinking of the B cell receptor by anti-IgM (78). These data suggest that there may be global defects in B cell activation in Stat1–/– mice that are not limited to TLR7-specific responses; however, further studies to characterize potential defects are necessary. B cell stimulation by CpGs through TLR9 and MyD88 promotes T cell–independent isotype switching to IgG2a through direct induction of the transcription factor T-bet (32, 79, 80). Because TLR7 also signals through MyD88, it is thought that signaling through TLR7 promotes a similar IgG2a response. In support of these studies, Irf9–/– mice immunized with OVA using a TLR7 agonist as an adjuvant failed to produce IgG2a OVA-specific antibodies in a pilot study (D.L. Thibault and P.J. Utz, unpublished observations); however, a larger cohort of mice is necessary to confirm these findings. The lack of isotype switching to IgG in Irf9–/– mice is not due to the inability of Irf9–/– B cells to upregulate T-bet, as T-bet was highly induced in Irf9–/– B cells following incubation with IFN-α together with TLR agonists (D.L. Thibault and P.J. Utz, unpublished observations). IFN-I together with IL-6 promotes B cell maturation to antibody-secreting plasma cells (43), providing further support for a role for IRF9 in B cell isotype switching. Further studies are necessary to dissect the complex role for IFN-I signaling in TLR7- and TLR9-dependent and -independent B cell responses and to determine the role of this pathway in other cell types in SLE pathogenesis.

In summary, our data demonstrate what we believe to be a novel role for 2 downstream mediators of IFN-I signaling in the generation of IgG autoantibody responses against nucleic acid–associated autoantigens. We propose that IFN-I, which is produced by pDCs in vivo following pristane treatment, promotes the expression of TLR7 and TLR9 in B cells through the ISGF3, allowing for the activation of autoreactive B cells by MCTD- and SLE-associated autoantigens and the production of high-titer, high-affinity IgG autoantibodies. A schematic outlining this proposed model is depicted in Supplemental Figure 7. Pristane treatment has previously been shown to induce apoptosis both in vitro and in vivo, providing a potential source of lupus-associated autoantigens (17). Our data suggest that IFN-I signaling is upstream of TLR responses in the activation of autoreactive B cells. Finally, specific inhibitors of IFN-I and TLRs are in preclinical or early-stage clinical trials for the treatment of SLE in human patients. Our results suggest that patients could be selected for clinical trials and monitored for response to therapy based on autoantibody profiles and provide a clear rationale for pursuing these therapeutic approaches.


Mice and treatment.

BALB/c mice were obtained from the Department of Laboratory Animal Medicine at Stanford University School of Medicine. Irf9–/– mice backcrossed onto the BALB/c background to the N8 generation were purchased from RIKEN BioResearch Center. Stat1–/– mice backcrossed onto the BALB/c background to the N9 generation were a generous gift from J. Durbin (Ohio State University, Columbus, Ohio, USA). All mice used in this study were maintained under standard conditions at the Stanford University Research Animal Facility. Female mice of 8–10 weeks of age were given a single 0.5-ml i.p. injection of pristane (Sigma-Aldrich) or 0.5 ml PBS. Sera were collected before injection and at 4-week intervals throughout the duration of the experiment. Proteinuria was monitored by dipstick analysis using Albustix (Bayer) on a monthly basis. All animal experiments were approved by, and performed in compliance with the guidelines of, the Institutional Animal Care and Use Committee of Stanford University.

Lupus autoantigen microarrays.

Autoantigens were diluted to 0.2 mg/ml in PBS and printed in ordered arrays on nitrocellulose-coated FAST slides (Whatman) using a VersArray ChipWriter Pro Robotic Arrayer (Bio-Rad). Individual arrays were circumscribed with a hydrophobic marker pap pen and blocked with PBS containing 3% fetal calf serum and 0.05% Tween 20 (Sigma-Aldrich) overnight at 4°C. Arrays were probed with 450 μl mouse serum diluted 1:300 for 2 hours at 4°C, followed by washing and incubation with a 1:2,000 dilution of cyanine-3–conjugated goat anti-mouse IgG/IgM secondary antibody (Jackson ImmunoResearch Laboratories). Arrays were scanned using a GenePix 4000B scanner (Molecular Devices). Detailed protocols and lists of antigens have been published previously (41).

The median pixel intensities of each feature were determined using GenePix Pro version 6.0 software (Molecular Devices), and background values were subtracted. Data were expressed as normalized median net digital fluorescence units, representing the median values from 8 replicate antigen features on each array normalized to the median intensity of 8 goat anti-mouse Ig features. SAM (47) was applied to the dataset to identify antigens with statistically significant differences in array reactivity between groups of mice. A hierarchical clustering algorithm was applied (45), and data were displayed using Java Treeview software (46).


All serological analysis was performed on sera obtained 6 months following treatment with pristane or PBS. For anti-ssDNA ELISAs, Nunc Maxisorp plates (Nalgene) were coated with 10 μg/ml calf thymus DNA (Sigma-Aldrich). For anti-histone, anti-Sm/RNP, anti-RiboP, and anti-OVA ELISAs, Maxisorp plates were coated with purified whole histones (Immunovision), Sm/RNP (Diarect), RiboP (Diarect), or OVA (Pierce) at a concentration of 1 μg/ml overnight at 4°C. Wells were incubated with mouse sera diluted 1:250 in PBS containing 3% FBS and 0.05% Tween-20 followed by incubation with HRP-conjugated goat anti-mouse IgG, IgM, IgG1, IgG2a, IgG2b, or IgG3 secondary antibody (Jackson ImmunoResearch Laboratories) at a dilution of 1:5,000. Tetramethylbenzidine substrate (Pierce) was added, and OD values were determined at 450 nm. Absorbances from blank wells (no serum added) were subtracted.

To determine levels of total serum Ig isotypes, plates were coated with 5 μg/ml goat anti-mouse Ig (heavy and light chain) antibody (Southern Biotechnology) overnight at 4°C. Wells were incubated with 1:5,000,000 dilution for IgG, or 1:500,000 dilution for all other isotypes, of sera in PBS containing 3% FBS and 0.05% Tween-20 followed by isotype-specific HRP-conjugated secondary goat anti-mouse antibody (Southern Biotechnology). Standard curves were constructed using mouse Ig isotype standards (Southern Biotechnology).

Real-time quantitative PCR.

Splenocytes were harvested from age- and sex-matched WT, Irf9–/–, and Stat1–/– mice. B cells were negatively selected using magnetic beads (Miltenyi Biotech). Cells were more than 95% pure, as assessed by flow cytometry (B220+biotin). B cells were cultured in RPMI supplemented with l-glutamine (2 mM), sodium pyruvate (1 mM), nonessential amino acids (0.1 mM), penicillin (100 U/ml), streptomycin (0.1 mg/ml), 2-ME (5 × 10–5 M), and FBS (10%) in the presence or absence of 1,000 IU/ml recombinant IFN-α (Calbiochem) for 4 hours. RNA was extracted using RNeasy Mini kit (Qiagen). RNA (10 ng) was amplified using 1-step QuantiTect SYBR Green RT-PCR (Qiagen) and 0.5 μM forward and reverse primers using an Opticon2 continuous fluorescence detector (MJ Research). The fold change in expression of each transcript normalized to GAPDH was determined by the 2–ΔΔCt method. QuantiTect Primer Assay sets for murine TLR7, TLR9, and GAPDH were purchased from Qiagen. Primer sequences for Mx1 were as follows: 5′-GATCCGACTTCACTTCCAGATGG-3′ (forward) and 5′-CATCTCAGTGGTAGTCAACCC-3′ (reverse).

Proliferation assay.

Whole splenocytes, or B cells purified as described above, were harvested from age- and sex-matched WT, Irf9–/–, or Stat1–/– mice and stimulated with 1 μM ODN1826 or 1 mM loxoribine (both from Invivogen) in triplicate. Cells were pulsed with 1 μCi [3H]TdR (Amersham) 16 hours following stimulation and harvested 24 hours following TLR stimulation. Incorporated radioactivity was measured using a betaplate scintillation counter.

IL-6 production.

Whole splenocytes or B cells were purified, cultured, and stimulated as described above. After 24 hours, supernatants were assayed for the production of IL-6 by sandwich ELISA using a commercially available kit (BD Biosciences — Pharmingen). For IFN-α pretreatment studies, purified B cells were incubated in the presence or absence of 1,000 IU/ml recombinant murine IFN-α (Calbiochem) for 24 hours. TLR ligands were added as described above, and IL-6 concentration in the supernatant was determined 24 hours following stimulation.

Adjuvant enhanced antibody responses.

Age- and sex-matched WT and Irf9–/– mice were immunized i.p. with 25 μg Imject OVA (Pierce) in PBS emulsified in CFA (Sigma-Aldrich) on day 0. Mice were boosted with 25 μg Imject OVA in PBS emulsified in IFA (Sigma-Aldrich) on day 14. Serum was collected from the mice on day 28 and assayed for the production of anti-OVA antibodies by ELISA.


Differences between and among groups were determined by Fisher’s exact test, Student’s t test, or Mann-Whitney test as indicated in the figure and table legends. A P value less than 0.05 was considered significant.

Supplementary Material

Supplemental data:


The authors thank T. Taniguchi for Irf9–/– mice; J. Durbin for Stat1–/– mice; and M.G. Kattah, S.M. Chan, P.P. Ho, J.L. Kanter, and other members of the Utz laboratory for technical assistance and helpful discussions. This work was supported by NIH grants AI051614 and AI40093; by National Heart, Lung, and Blood Institute Proteomics contract N01-HV-28183; by a grant from the Northern California Chapter of the Arthritis Foundation; by the Lupus Foundation of America; and by a gift from the Floren Family Trust to P.J. Utz. D.L. Thibault and A. Landrigan are recipients of National Science Foundation Graduate Research Fellowships. D.L. Thibault is the recipient of a P.E.O. Sisterhood Scholar Award. A.D. Chu is supported by an American College of Rheumatology Physician Scientist Development Award and by the Training Program in Adult and Pediatric Rheumatology (5 T32 AR050942). K.L. Graham is the recipient of an NIH National Research Service Award Fellowship (AI-10663-02). I. Balboni is the recipient of an Arthritis Foundation postdoctoral fellowship. C. Kohlmoos is the recipient of a Center for Clinical Immunology at Stanford (CCIS) Summer Research Program Fellowship.


Nonstandard abbreviations used: FDR, false discovery rate; IFA, incomplete Freund adjuvant; IFNAR, IFN (α and β) receptor; IFN-I, type I IFN; IRF, IFN regulatory factor; ISGF, IFN-stimulated gene factor; MCTD, mixed connective tissue disease; ODN, oligodeoxynucleotide; pDC, plasmacytoid dendritic cell; RiboP, ribosomal phosphoprotein P0; RNP, ribonucleoprotein; SAM, significance analysis of microarrays; Sm, Smith antigen; ssDNA, single-stranded DNA; U1snRNP, U1 small nuclear RNP.

Conflict of interest: P.J. Utz has served as a consultant to Centocor, Biogen/Idec, Avanir Inc., and Genentech Inc.; is a member of the Scientific Advisory Board of Monogram Biosciences, XDx Inc., and Argos Therapeutics; and is a cofounder and consultant at Bayhill Therapeutics. The remaining authors have declared that no conflict of interest exists.

Citation for this article: J. Clin. Invest. 118:1417–1426 (2008). doi:10.1172/JCI30065


1. Hooks J.J., et al. Immune interferon in the circulation of patients with autoimmune disease. N. Engl. J. Med. 1979;301:5–8. [PubMed]
2. Bennett L., et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 2003;197:711–723. doi: 10.1084/jem.20021553. [PMC free article] [PubMed] [Cross Ref]
3. Baechler E.C., et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. U. S. A. 2003;100:2610–2615. [PubMed]
4. Kirou K.A., et al. Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum. 2004;50:3958–3967. doi: 10.1002/art.20798. [PubMed] [Cross Ref]
5. Bauer J.W., et al. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med. 2006;3:e491. [PubMed]
6. Ronnblom L.E., Alm G.V., Oberg K.E. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann. Intern. Med. 1991;115:178–183. [PubMed]
7. Durbin J.E., Hackenmiller R., Simon M.C., Levy D.E. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell. 1996;84:443–450. doi: 10.1016/S0092-8674(00)81289-1. [PubMed] [Cross Ref]
8. Kimura T., et al. Essential and non-redundant roles of p48 (ISGF3 gamma) and IRF-1 in both type I and type II interferon responses, as revealed by gene targeting studies. Genes Cells. 1996;1:115–124. doi: 10.1046/j.1365-2443.1996.08008.x. [PubMed] [Cross Ref]
9. Harada H., et al. Regulation of IFN-alpha/beta genes: evidence for a dual function of the transcription factor complex ISGF3 in the production and action of IFN-alpha/beta. Genes Cells. 1996;1:995–1005. doi: 10.1046/j.1365-2443.1996.870287.x. [PubMed] [Cross Ref]
10. Bluyssen H.A., et al. Combinatorial association and abundance of components of interferon-stimulated gene factor 3 dictate the selectivity of interferon responses. Proc. Natl. Acad. Sci. U. S. A. 1995;92:5645–5649. doi: 10.1073/pnas.92.12.5645. [PubMed] [Cross Ref]
11. Matsumoto M., et al. Activation of the transcription factor ISGF3 by interferon-gamma. Biol. Chem. 1999;380:699–703. doi: 10.1515/BC.1999.087. [PubMed] [Cross Ref]
12. Hua J., Kirou K., Lee C., Crow M.K. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum. 2006;54:1906–1916. doi: 10.1002/art.21890. [PubMed] [Cross Ref]
13. Zhuang H., et al. Association of anti-nucleoprotein autoantibodies with upregulation of Type I interferon-inducible gene transcripts and dendritic cell maturation in systemic lupus erythematosus. Clin. Immunol. 2005;117:238–250. doi: 10.1016/j.clim.2005.07.009. [PubMed] [Cross Ref]
14. Satoh M., Kumar A., Kanwar Y.S., Reeves W.H. Anti-nuclear antibody production and immune-complex glomerulonephritis in BALB/c mice treated with pristane. Proc. Natl. Acad. Sci. U. S. A. 1995;92:10934–10938. doi: 10.1073/pnas.92.24.10934. [PubMed] [Cross Ref]
15. Satoh M., Reeves W.H. Induction of lupus-associated autoantibodies in BALB/c mice by intraperitoneal injection of pristane. J. Exp. Med. 1994;180:2341–2346. doi: 10.1084/jem.180.6.2341. [PMC free article] [PubMed] [Cross Ref]
16. Kattah M.G., Alemi G.R., Thibault D.L., Balboni I., Utz P.J. A new two-color Fab labeling method for autoantigen protein microarrays. Nat. Methods. 2006;3:745–751. doi: 10.1038/nmeth910. [PubMed] [Cross Ref]
17. Calvani N., et al. Induction of apoptosis by the hydrocarbon oil pristane: implications for pristane-induced lupus. J. Immunol. 2005;175:4777–4782. [PubMed]
18. Nacionales D.C., et al. Type I interferon production by tertiary lymphoid tissue developing in response to 2,6,10,14-tetramethyl-pentadecane (pristane). Am. J. Pathol. 2006;168:1227–1240. doi: 10.2353/ajpath.2006.050125. [PubMed] [Cross Ref]
19. Hamilton K.J., Satoh M., Swartz J., Richards H.B., Reeves W.H. Influence of microbial stimulation on hypergammaglobulinemia and autoantibody production in pristane-induced lupus. Clin. Immunol. Immunopathol. 1998;86:271–279. doi: 10.1006/clin.1997.4481. [PubMed] [Cross Ref]
20. Vallin H., Blomberg S., Alm G.V., Cederblad B., Ronnblom L. Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-alpha (IFN-alpha) production acting on leucocytes resembling immature dendritic cells. Clin. Exp. Immunol. 1999;115:196–202. doi: 10.1046/j.1365-2249.1999.00772.x. [PubMed] [Cross Ref]
21. Lovgren T., Eloranta M.L., Bave U., Alm G.V., Ronnblom L. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum. 2004;50:1861–1872. doi: 10.1002/art.20254. [PubMed] [Cross Ref]
22. Vallin H., Perers A., Alm G.V., Ronnblom L. Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus. J. Immunol. 1999;163:6306–6313. [PubMed]
23. Means T.K., et al. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J. Clin. Invest. 2005;115:407–417. [PMC free article] [PubMed]
24. Leadbetter E.A., et al. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature. 2002;416:603–607. doi: 10.1038/416603a. [PubMed] [Cross Ref]
25. Savarese E., et al. U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7. Blood. 2006;107:3229–3234. doi: 10.1182/blood-2005-07-2650. [PubMed] [Cross Ref]
26. Lovgren T., et al. Induction of interferon-alpha by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sjogren’s syndrome autoantigen-associated RNA. Arthritis Rheum. 2006;54:1917–1927. doi: 10.1002/art.21893. [PubMed] [Cross Ref]
27. Kelly K.M., et al. “Endogenous adjuvant” activity of the RNA components of lupus autoantigens Sm/RNP and Ro 60. Arthritis Rheum. 2006;54:1557–1567. doi: 10.1002/art.21819. [PubMed] [Cross Ref]
28. Vollmer J., et al. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J. Exp. Med. 2005;202:1575–1585. doi: 10.1084/jem.20051696. [PMC free article] [PubMed] [Cross Ref]
29. Lau C.M., et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J. Exp. Med. 2005;202:1171–1177. doi: 10.1084/jem.20050630. [PMC free article] [PubMed] [Cross Ref]
30. Barrat F.J., et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J. Exp. Med. 2005;202:1131–1139. doi: 10.1084/jem.20050914. [PMC free article] [PubMed] [Cross Ref]
31. Hoffman R.W., et al. U1 RNA induces innate immunity signaling. Arthritis Rheum. 2004;50:2891–2896. doi: 10.1002/art.20428. [PMC free article] [PubMed] [Cross Ref]
32. Ehlers M., Fukuyama H., McGaha T.L., Aderem A., Ravetch J.V. TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J. Exp. Med. 2006;203:553–561. doi: 10.1084/jem.20052438. [PMC free article] [PubMed] [Cross Ref]
33. Christensen S.R., et al. Toll-like Receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity. 2006;25:417–428. doi: 10.1016/j.immuni.2006.07.013. [PubMed] [Cross Ref]
34. Subramanian S., et al. A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. Proc. Natl. Acad. Sci. U. S. A. . 2006;103:9970–9975. doi: 10.1073/pnas.0603912103. [PubMed] [Cross Ref]
35. Pisitkun P., et al. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science. 2006;312:1669–1672. doi: 10.1126/science.1124978. [PubMed] [Cross Ref]
36. Bar-Or A., et al. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. Arch. Neurol. 2007;64:1407–1415. doi: 10.1001/archneur.64.10.nct70002. [PubMed] [Cross Ref]
37. Sekine H., et al. Role of MHC-linked genes in autoantigen selection and renal disease in a murine model of systemic lupus erythematosus. J. Immunol. 2006;177:7423–7434. [PubMed]
38. Graham K.L., Vaysberg M., Kuo A., Utz P.J. Autoantigen arrays for multiplex analysis of antibody isotypes. Proteomics. 2006;6:5720–5724. doi: 10.1002/pmic.200600345. [PubMed] [Cross Ref]
39. Balboni I., et al. Multiplexed protein array platforms for analysis of autoimmune diseases. Annu. Rev. Immunol. 2006;24:391–418. doi: 10.1146/annurev.immunol.24.021605.090709. [PubMed] [Cross Ref]
40. Hueber W., et al. Antigen microarray profiling of autoantibodies in rheumatoid arthritis. Arthritis Rheum. 2005;52:2645–2655. doi: 10.1002/art.21269. [PubMed] [Cross Ref]
41. Robinson W.H., et al. Autoantigen micro­arrays for multiplex characterization of autoantibody responses. Nat. Med. 2002;8:295–301. doi: 10.1038/nm0302-295. [PubMed] [Cross Ref]
42. Le Bon A., et al. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity. 2001;14:461–470. doi: 10.1016/S1074-7613(01)00126-1. [PubMed] [Cross Ref]
43. Jego G., et al. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity. 2003;19:225–234. doi: 10.1016/S1074-7613(03)00208-5. [PubMed] [Cross Ref]
44. Snapper C.M., Paul W.E. Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science. 1987;236:944–947. doi: 10.1126/science.3107127. [PubMed] [Cross Ref]
45. Eisen M.B., Spellman P.T., Brown P.O., Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. U. S. A. 1998;95:14863–14868. doi: 10.1073/pnas.95.25.14863. [PubMed] [Cross Ref]
46. Saldanha A.J. Java Treeview — extensible visualization of microarray data. Bioinformatics. 2004;20:3246–3248. doi: 10.1093/bioinformatics/bth349. [PubMed] [Cross Ref]
47. Tusher V.G., Tibshirani R., Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. U. S. A. 2001;98:5116–5121. [PubMed]
48. Richards H.B., et al. Interleukin 6 dependence of anti-DNA antibody production: evidence for two pathways of autoantibody formation in pristane-induced lupus. J. Exp. Med. 1998;188:985–990. doi: 10.1084/jem.188.5.985. [PMC free article] [PubMed] [Cross Ref]
49. Bekeredjian-Ding I.B., et al. Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. J. Immunol. 2005;174:4043–4050. [PubMed]
50. Gavin A.L., et al. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science. 2006;314:1936–1938. doi: 10.1126/science.1135299. [PMC free article] [PubMed] [Cross Ref]
51. Austin H.A., 3rd, Muenz L.R., Joyce K.M., Antonovych T.T., Balow J.E. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int. 1984;25:689–695. doi: 10.1038/ki.1984.75. [PubMed] [Cross Ref]
52. Potter M., Wax J.S. Peritoneal plasmacytomagenesis in mice: comparison of different pristane dose regimens. J. Natl. Cancer Inst. 1983;71:391–395. [PubMed]
53. Kumar A., Commane M., Flickinger T.W., Horvath C.M., Stark G.R. Defective TNF-alpha-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases. Science. 1997;278:1630–1632. doi: 10.1126/science.278.5343.1630. [PubMed] [Cross Ref]
54. Bromberg J.F., Horvath C.M., Wen Z., Schreiber R.D., Darnell J.E., Jr. Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. Proc. Natl. Acad. Sci. U. S. A. 1996;93:7673–7678. doi: 10.1073/pnas.93.15.7673. [PubMed] [Cross Ref]
55. Vannucchi S., et al. Perspectives in biomolecular therapeutic intervention in cancer: from the early to the new strategies with type I interferons. Curr. Med. Chem. 2007;14:667–679. doi: 10.2174/092986707780059616. [PubMed] [Cross Ref]
56. Sharp G.C., et al. Association of autoantibodies to different nuclear antigens with clinical patterns of rheumatic disease and responsiveness to therapy. J. Clin. Invest. 1971;50:350–359. doi: 10.1172/JCI106502. [PMC free article] [PubMed] [Cross Ref]
57. Query C.C., Keene J.D. A human autoimmune protein associated with U1 RNA contains a region of homology that is cross-reactive with retroviral p30gag antigen. Cell. 1987;51:211–220. doi: 10.1016/0092-8674(87)90148-6. [PubMed] [Cross Ref]
58. Lerner M.R., Andrews N.C., Miller G., Steitz J.A. Two small RNAs encoded by Epstein-Barr virus and complexed with protein are precipitated by antibodies from patients with systemic lupus erythematosus. Proc. Natl. Acad. Sci. U. S. A. 1981;78:805–809. doi: 10.1073/pnas.78.2.805. [PubMed] [Cross Ref]
59. Utz P.J., Anderson P. Posttranslational protein modifications, apoptosis, and the bypass of tolerance to autoantigens. Arthritis Rheum. 1998;41:1152–1160. doi: 10.1002/1529-0131(199807)41:7<1152::AID-ART3>3.0.CO;2-L. [PubMed] [Cross Ref]
60. Nacionales D.C., et al. Deficiency of the type I interferon receptor protects mice from experimental lupus. Arthritis Rheum. 2007;56:3770–3783. doi: 10.1002/art.23023. [PMC free article] [PubMed] [Cross Ref]
61. Richards H.B., et al. Interferon-gamma is required for lupus nephritis in mice treated with the hydrocarbon oil pristane. Kidney Int. 2001;60:2173–2180. doi: 10.1046/j.1523-1755.2001.00045.x. [PubMed] [Cross Ref]
62. Rothlin C.V., Ghosh S., Zuniga E.I., Oldstone M.B., Lemke G. TAM receptors are pleiotropic inhibitors of the innate immune response. Cell. 2007;131:1124–1136. doi: 10.1016/j.cell.2007.10.034. [PubMed] [Cross Ref]
63. Hanada T., et al. Suppressor of cytokine signaling-1 is essential for suppressing dendritic cell activation and systemic autoimmunity. Immunity. 2003;19:437–450. doi: 10.1016/S1074-7613(03)00240-1. [PubMed] [Cross Ref]
64. Lu Q., Lemke G. Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science. 2001;293:306–311. doi: 10.1126/science.1061663. [PubMed] [Cross Ref]
65. Sharif M.N., et al. Twist mediates suppression of inflammation by type I IFNs and Axl. J. Exp. Med. 2006;203:1891–1901. doi: 10.1084/jem.20051725. [PMC free article] [PubMed] [Cross Ref]
66. Taniguchi T., Ogasawara K., Takaoka A., Tanaka N. IRF family of transcription factors as regulators of host defense. Annu. Rev. Immunol. 2001;19:623–655. doi: 10.1146/annurev.immunol.19.1.623. [PubMed] [Cross Ref]
67. Graham R.R., et al. Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc. Natl. Acad. Sci. U. S. A. 2007;104:6758–6763. doi: 10.1073/pnas.0701266104. [PubMed] [Cross Ref]
68. Graham R.R., et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat. Genet. 2006;38:550–555. doi: 10.1038/ng1782. [PubMed] [Cross Ref]
69. Sigurdsson S., et al. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am. J. Hum. Genet. 2005;76:528–537. doi: 10.1086/428480. [PubMed] [Cross Ref]
70. Yasuda K., et al. Murine dendritic cell type I IFN production induced by human IgG-RNA immune complexes is IFN regulatory factor (IRF)5 and IRF7 dependent and is required for IL-6 production. J. Immunol. 2007;178:6876–6885. [PubMed]
71. Honda K., et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature. 2005;434:772–777. doi: 10.1038/nature03464. [PubMed] [Cross Ref]
72. Reilly C.M., et al. Interferon regulatory factor-1 gene deletion decreases glomerulonephritis in MRL/lpr mice. Eur. J. Immunol. 2006;36:1296–1308. doi: 10.1002/eji.200535245. [PubMed] [Cross Ref]
73. Fanzo J.C., et al. Loss of IRF-4-binding protein leads to the spontaneous development of systemic autoimmunity. J. Clin. Invest. 2006;116:703–714. doi: 10.1172/JCI24096. [PMC free article] [PubMed] [Cross Ref]
74. Christensen S.R., et al. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J. Exp. Med. 2005;202:321–331. doi: 10.1084/jem.20050338. [PMC free article] [PubMed] [Cross Ref]
75. Hron J.D., Peng S.L. Type I IFN protects against murine lupus. J. Immunol. 2004;173:2134–2142. [PubMed]
76. Liu J., et al. Genomic view of systemic autoimmunity in MRLlpr mice. Genes Immun. 2006;7:156–168. doi: 10.1038/sj.gene.6364286. [PubMed] [Cross Ref]
77. Yoshida H., et al. Effect of an exogenous trigger on the pathogenesis of lupus in (NZB x NZW)F1 mice. Arthritis Rheum. 2002;46:2235–2244. doi: 10.1002/art.10441. [PMC free article] [PubMed] [Cross Ref]
78. Frissora F., Chen H.C., Durbin J., Bondada S., Muthusamy N. IFN-gamma-mediated inhibition of antigen receptor-induced B cell proliferation and CREB-1 binding activity requires STAT-1 transcription factor. Eur. J. Immunol. 2003;33:907–912. doi: 10.1002/eji.200323657. [PubMed] [Cross Ref]
79. Liu N., Ohnishi N., Ni L., Akira S., Bacon K.B. CpG directly induces T-bet expression and inhibits IgG1 and IgE switching in B cells. Nat. Immunol. 2003;4:687–693. doi: 10.1038/ni941. [PubMed] [Cross Ref]
80. Gerth A.J., Lin L., Peng S.L. T-bet regulates T-independent IgG2a class switching. Int. Immunol. 2003;15:937–944. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation